BusinessOncothyreon Appoints Scott D. Myers Chief Executive OfficerBy Nasdaq OMXMar 29, 2016, 12:00 PM UTC
BusinessOncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 8, 2015, 9:05 PM UTC
BusinessOncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer PatientsBy Nasdaq OMXDec 2, 2015, 1:00 PM UTC
